AI-assisted assay to evaluate the dose-response mechanism of skin sensitizers
CompanySenzaGen, Lund, Sweden
The company SenzaGen specializes in the development of AI-based test methods for identifying and evaluating skin allergens. The GARD®skin Dose-Response Platform is a modified variant of the GARD®skin assay, which distinguishes sensitizing and non-sensitizing substances with over 90% accuracy and subcategorizes them into strong and weak sensitizers (1A and 1B) according to the GHS/ CLP system enables. To predict the biochemical properties of a substance, a machine learning platform generates a biomarker signature of an exposed test sample, which is compared to existing data sets. The GARD®skin Dose-Response Assay not only enables the hazard classification of an active substance, but also evaluates the potency of the test substance; i.e. it determines the minimum quantitative active ingredient concentration that is sufficient to induce an allergic reaction in the skin and thereby enables an early ranking of potential active ingredient candidates. The method delivers meaningful results within a period of 4–8 weeks that correlate with the measured values of previous established methods. In summary, the modified assay proves to be a valuable tool for the predictive evaluation of chemicals and other substances to be tested, which can help to optimize risk management in early drug and medical device development and to accelerate previously time-consuming testing procedures.
GARD®skin Dose-Response. In vitro quantitative assessment of skin sensitizing potency
info@senzagen.com
Added on: 11-21-2023
[1] https://senzagen.com/gardskin-dose-response/
